Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.35 |
| ▸ | FLT1 | P17948 | 3/20 | 0.35 |
| ▸ | FLT4 | P35916 | 3/20 | 0.35 |
| ▸ | GRM5 | P41594 | 5/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22925792 | 0.86 | KDR (0.35) | KDRFLT1FLT4GRM5MEN1 | |
| SCHEMBL22925712 | 0.85 | ALOX5 (0.47) | KDRFLT1FLT4ALOX5MEN1 | |
| SCHEMBL24636937 | 0.85 | NPSR1 (0.39) | KDRFLT1FLT4NPC1RAB9A | |
| SCHEMBL29620869 | 0.85 | NPSR1 (0.39) | KDRFLT1FLT4NPC1RAB9A | |
| SCHEMBL22925742 | 0.83 | CHEK1 (0.40) | KDRFLT1FLT4GRM5ALOX5 | |
| SCHEMBL29620891 | 0.83 | CHEK1 (0.40) | KDRFLT1FLT4GRM5ALOX5 | |
| SCHEMBL29621019 | 0.78 | KDR (0.39) | KDRFLT1FLT4ALOX5IMPDH2 | |
| SCHEMBL22925562 | 0.78 | KDR (0.39) | KDRFLT1FLT4ALOX5IMPDH2 | |
| SCHEMBL22925599 | 0.76 | ALOX5 (0.34) | KDRALOX5MEN1NPC1RAB9A | |
| SCHEMBL22926082 | 0.75 | TRPV1 (0.47) | KDRFLT1FLT4IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450281-B | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| EP-4003986-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450281-A | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021012018-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | KDR 3951/4885FLT1 2567/4885FLT4 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.